(19)
(11) EP 1 694 845 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.12.2017 Bulletin 2017/51

(45) Mention of the grant of the patent:
05.07.2017 Bulletin 2017/27

(21) Application number: 04761652.9

(22) Date of filing: 17.08.2004
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
C07K 16/30(2006.01)
C12N 15/13(2006.01)
C07K 14/245(2006.01)
C07K 19/00(2006.01)
G01N 33/574(2006.01)
(86) International application number:
PCT/CA2004/001488
(87) International publication number:
WO 2005/052158 (09.06.2005 Gazette 2005/23)

(54)

ANTICARCINOMA ANTIBODIES AND USES THEREOF

ANTIKARZINOM-ANTIKÖRPER UND VERWENDUNGEN DAVON

ANTICORPS ANTICARCINOMES ET LEURS UTILISATIONS


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 28.11.2003 US 525183 P

(43) Date of publication of application:
30.08.2006 Bulletin 2006/35

(73) Proprietors:
  • National Research Council of Canada
    Ottawa, Ontario K1A 0R6 (CA)
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6 (CA)

(72) Inventors:
  • MACKENZIE, Colin, Roger
    Ottawa, Ontario K1J 6K9 (CA)
  • ZHANG, Jianbing
    Ottawa, Ontario K1W 1G7 (CA)
  • NGUYEN, Thanh-Dung
    Ottawa, Ontario K1J 7G5 (CA)
  • LI, Qinggang
    Ottawa, Ontario K2J 4Y1 (CA)
  • MAI, Kien Trung
    Ottawa, Ontario K1R 7K1 (CA)

(74) Representative: Fleuchaus, Michael A. et al
Fleuchaus & Gallo Partnerschaft mbB Patent- und Rechtsanwälte Steinerstrasse 15/A
81369 München
81369 München (DE)


(56) References cited: : 
WO-A-00/52054
WO-A-03/055527
WO-A1-00/58335
US-A- 5 593 847
WO-A-97/20932
WO-A-2004/078097
WO-A2-03/046560
   
  • ZHANG J ET AL: "A Pentavalent Single-domain Antibody Approach to Tumor Antigen Discovery and the Development of Novel Proteomics Reagents" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 341, no. 1, 30 July 2004 (2004-07-30), pages 161-169, XP004679996 ISSN: 0022-2836
  • KUROKI M ET AL: "Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker." ANTICANCER RESEARCH 1999 NOV-DEC, vol. 19, no. 6C, November 1999 (1999-11), pages 5599-5606, XP008091618 ISSN: 0250-7005
  • SCHOELZEL S ET AL: "Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas" AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 156, no. 2, 1 February 2000 (2000-02-01), pages 595-605, XP002214009 ISSN: 0002-9440
  • PIMENIDOU A ET AL: "Bacteriophage-derived antibodies in cancer research--diagnosis, imaging, and treatment." DISEASE MARKERS 2000, vol. 16, no. 1-2, 2000, pages 41-51, XP008091581 ISSN: 0278-0240
  • JANTSCHEFF P ET AL: "Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance" NAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 21, no. 19, 1 October 2003 (2003-10-01), pages 3638-3646, XP002992202 ISSN: 0732-183X
  • MAI K T ET AL: "ES1, a new lung carcinoma antibody--an immunohistochemical study." HISTOPATHOLOGY NOV 2006, vol. 49, no. 5, November 2006 (2006-11), pages 515-522, XP002480851 ISSN: 0309-0167
  • HARMSEN M M ET AL: "Properties, production, and applications of camelid single-domain antibody fragments" APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER-VERLAG, BE, vol. 77, no. 1, 18 August 2007 (2007-08-18), pages 13-22, XP019560673 ISSN: 1432-0614
  • DATABASE DGENE [Online] FLETCHER ET AL.: 'Alloiococcus otitis antigenic peptide', XP008095995 Database accession no. ADB07483 & WO 03 004834 A1
  • DATABASE PMID [Online] ZHANG ET AL.: 'A pentavalent single-domain antibody approach to tumour antigen discovery and the development of novel proteomics reagents', XP008095994 Database accession no. 14659739 & JOURNAL OF MOLECURAL BIOLOGY vol. 341, no. 1, 30 July 2004, AMSTREDAM, NL, pages 161 - 169
  • DATABASE PMID [Online] ZHANG ET AL.: 'pentamerization of single-domain antibodies from phage libraries a novel strategy for the rapid generation of high-avidity antibody reagents', XP008095993 Database accession no. 14659739 & JOURNAL OF MOLECULAR BIOLOGY vol. 335, 02 January 2004, AMSTREDAM, NL, pages 49 - 56
  • TERSKIKH ET AL.: 'Pentabody: a new type of high avidity binding protein' PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES vol. 94, no. 5, 1997, WASHINGTON DC, USA, pages 1663 - 1668, XP002147182
  • TANHA ET AL.: 'Phage display technology for identifying specific antigens on brain endothelail cells' METHODS IN MOLECULAR MEDICINE, THE BLOOD-BRAIN BARRIER 2003, HUMANA PRESS, TOTOWA, NJ, USA, pages 435 - 449, XP008070012
  • BRICHORY ET AL.: 'Proteomics-based identification of protein gene product 9.5 as a tumour antigen that induces a humoral immune response in lung cancer' CANCER RESEARCH vol. 61, no. 21, 01 November 2003, pages 7908 - 7912, XP002960163
  • ELS CONRATH ET AL.: 'Camel single-domain antibodies as modular building units in biospecific & bivalent antibody constructs' JOURNAL OF BIOLOGICAL CHEMISTRY,THE AMERICAN SOCIETY FOR BIOCHEMICAL AND MOLECULAR BIOLOGY vol. 276, no. 10, 09 March 2001, pages 7346 - 7350, XP002248402
  • ALFTHAN K ET AL: "Properties of a single-chain antibody containing different linker peptides", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 8, no. 7, 1 July 1995 (1995-07-01), pages 725-731, XP002112077, ISSN: 0269-2139
  • PINI A ET AL: "PHAGE DISPLAY OF ANTIBODY FRAGMENTS", CURRENT PROTEIN AND PEPTIDE SCIENCE, BENTHAM SCIENCE PULBISHERS, NL, vol. 1, no. 2, 1 September 2000 (2000-09-01), pages 155-169, XP001084580, ISSN: 1389-2037
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).